[Vaccination therapy for Alzheimer's disease]

Area of Science:

• Neuroscience
• Immunology
• Vaccinology

Context:

• Alzheimer's disease (AD) is a neurodegenerative disorder marked by beta-amyloid (A-beta) plaques and neuroinflammation.
• Previous active immunization strategies targeting A-beta reduced plaques but caused severe side effects like meningoencephalitis in human trials.
• The gut's immune system naturally suppresses T-helper 1 (Th1) responses, offering a potential avenue for safer AD therapies.

Purpose:

• To develop a safe and effective oral vaccine for Alzheimer's disease.
• To investigate the efficacy of an adeno-associated virus (AAV) vector-based oral A-beta vaccine in reducing amyloid burden.
• To evaluate the safety profile of the oral vaccine in preclinical models.

Summary:

• A novel oral vaccine utilizing an AAV vector was developed to deliver beta-amyloid (A-beta) antigen.
• Administration of the oral vaccine induced sustained high antibody titers against A-beta for over six months in preclinical models.
• Significant reduction in amyloid burden was observed in both amyloid precursor protein (APP) transgenic mice and aged monkeys without any adverse effects.

Impact:

• This oral A-beta vaccine represents a promising, safe therapeutic strategy for Alzheimer's disease treatment and prevention.
• The vaccine's ability to reduce amyloid burden without inducing autoimmune responses addresses the critical safety concerns of previous immunization methods.
• Harnessing the tolerogenic properties of the gut immune system offers a novel approach to managing neurodegenerative diseases like Alzheimer's.